Nianjun J Tao

58719873, Feb 16, 1999

Nov 1, 1996

8/743130

Mandana Sassanfar - Dedham MA
Paul L. Gallant - Dedham MA
Xiaoyu Shen - S. Boston MA
Nianjun Tao - Malden MA
Jianshi Tao - North Andover MA
Fariba Houman - Belmont MA

Cubist Pharmaceuticals, Inc. - Cambridge MA

C12N 900
C12N 114
C12N 1500
C07H 2104

435183

The present invention relates to isolated and/or recombinant nucleic acids which encode Candida tyrosyl-tRNA synthetases, portions thereof, or fusion proteins comprising a Candida tyrosyl-tRNA synthetase or portion thereof. Also disclosed are constructs comprising the nucleic acids of the present invention, host cells comprising a recombinant nucleic acid or construct, and methods of producing a Candida tyrosyl-tRNA synthetase, portion thereof, or fusion protein comprising same. Also described are tester strains, which are cells engineered to rely on the function of a Candida tyrosyl-tRNA synthetase or functional fragment thereof encoded by an introduced cloned gene, and which can be used in a method of detecting an inhibitor of Candida tyrosyl-tRNA synthetase function. The invention further relates to isolated and/or recombinant Candida tyrosyl-tRNA synthetases, portions thereof, or fusion proteins comprising a Candida tyrosyl-tRNA synthetase or portion thereof, methods of use of these polypeptides in an assay to identify inhibitors of Candida tyrosyl-tRNA synthetase function, and antibodies reactive with Candida tyrosyl-tRNA synthetases.

20210330612, Oct 28, 2021

Dec 6, 2019

17/299948

- Boston MA, US
Teeru BIHANI - Boston MA, US
Heike ARLT - Arlington MA, US
Nianjun TAO - Medford MA, US

A61K 31/137
A61P 35/00
C12Q 1/6886

Disclosed herein are methods of treating a CDK4/6 inhibitor resistant estrogen receptor alpha-positive cancer in a subject having either a wild-type estrogen receptor alpha and/or a mutant estrogen receptor alpha, the method comprising administering to the subject a therapeutically effective amount of elacestrant, or a pharmaceutically acceptable salt or solvate thereof, wherein the mutant estrogen receptor alpha comprises one or more mutations selected from the group consisting of D538G, Y537X, L536X, P535H, V534E, S463P, V392I, E380Q and combinations thereof, wherein: Xis S, N, or C; and Xis R or Q. In some embodiments, the CDK4/6 inhibitor resistant estrogen receptor alpha-positive cancer is selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, and pituitary cancer.

20210101968, Apr 8, 2021

Mar 19, 2020

16/824034

- Cambridge MA, US
Sandra Abbott - Boston MA, US
Ailin Bai - Newton MA, US
Ting Chen - Acton MA, US
Maria Isabel Chiu - Newton Centre MA, US
Qing Liu - Acton MA, US
Laura Poling - Boston MA, US
Nianjun Tao - Brighton MA, US
Solly Weiler - Newton MA, US
Zhigang Weng - Brookline MA, US
Jeno Gyuris - Lincoln MA, US

C07K 16/22
A61P 3/02
A61K 39/395
A61K 45/06

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

20180142013, May 24, 2018

Jul 20, 2017

15/655263

- Cambridge MA, US
Sandra Abbott - Boston MA, US
Ailin Bai - Newton MA, US
Ting Chen - Acton MA, US
Maria I. Chiu - Newton Centre MA, US
Qing Liu - Acton MA, US
Laura Poling - Boston MA, US
Nianjun Tao - Brighton MA, US
Solly Weiler - Newton MA, US
Zhigang Weng - Brookline MA, US
Jeno Gyuris - Lincoln MA, US

C07K 16/22
A61K 39/395
A61K 45/06

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

20160083465, Mar 24, 2016

Sep 24, 2015

14/863870

- Cambridge MA, US
Sandra Abbott - Boston MA, US
Ailin Bai - Newton MA, US
Ting Chen - Acton MA, US
Maria I. Chiu - Newton Centre MA, US
Qing Liu - Acton MA, US
Laura Poling - Boston MA, US
Nianjun Tao - Brighton MA, US
Solly Weiler - Newton MA, US
Zhigang Weng - Brookline MA, US
Jeno Gyuris - Lincoln MA, US

C07K 16/22
A61K 45/06
A61K 39/395

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

20140193427, Jul 10, 2014

Dec 20, 2013

14/137415

- Cambridge MA, US
Sandra Abbott - Boston MA, US
Ailin Bai - Newton MA, US
Ting Chen - Acton MA, US
Maria Isabel Chiu - Newton Centre MA, US
Qing Liu - Acton MA, US
Laura Poling - Boston MA, US
Nianjun Tao - Brighton MA, US
Solly Weiler - Newton MA, US
Zhigang Weng - Brookline MA, US
Jeno Gyuris - Lincoln MA, US

AVEO PHARMACEUTICALS, INC. - Cambridge MA

C07K 16/22

4241581, 5303892, 536 2353, 4353201, 43525233, 435 696, 435335

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.